Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness

Tsutomu Ishihara, Tetsushi Kubota, Tesu Choi, Miyuki Takahashi, Eri Ayano, Hideko Kanazawa, Megumu Higaki

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The purpose of this study was to engineer nanoparticles with various sustained profiles of drug release and prolonged circulation by blending poly(d,l-lactic acid)/poly(d,l-lactic/glycolic acid) (PLA/PLGA) homopolymers and poly(ethylene glycol) (PEG)-block-PLA/PLGA copolymers encapsulating betamethasone disodium 21-phosphate (BP). Nanoparticles of different sizes, drug encapsulation/release profiles, and cellular uptake levels were obtained by mixing homopolymers and block copolymers with different compositions/molecular weights at various blend ratios by an oil-in-water solvent diffusion method. The in vitro release of BP increased with nanoparticles of smaller size or of PLGA homopolymers instead of PLA homopolymers. Furthermore, the uptake of nanoparticles by macrophage-like cells decreased with nanoparticles of higher PEG content, and nanoparticles of PEG-PLGA block copolymers were taken up earlier than those of PEG-PLA block copolymers after incubation with serum. In addition, prolonged blood circulation was observed with nanoparticles of smaller size with higher PEG content, and nanoparticles of PEG-PLA block copolymers remained longer in circulation than those of PEG-PLGA block copolymers. Analysis of BP concentration in organs revealed reduced liver distribution of blended nanoparticles compared with PLA nanoparticles. This is the first study to systematically design and characterize biodegradable PLA/PLGA and PEG-PLA/PLGA-blended nanoparticles encapsulating BP with different release profiles and stealthiness.

Original languageEnglish
Pages (from-to)148-154
Number of pages7
JournalInternational Journal of Pharmaceutics
Volume375
Issue number1-2
DOIs
Publication statusPublished - 2009 Jun 22

Fingerprint

Nanoparticles
glycolic acid
betamethasone sodium phosphate
Ethylene Glycol
poly(lactic acid)
Blood Circulation
Oils
Molecular Weight
Macrophages
Water
Liver

Keywords

  • Betamethasone disodium 21-phosphate
  • Biodistribution
  • Drug release
  • Nanoparticles
  • PEG
  • PLA/PLGA polymers

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. / Ishihara, Tsutomu; Kubota, Tetsushi; Choi, Tesu; Takahashi, Miyuki; Ayano, Eri; Kanazawa, Hideko; Higaki, Megumu.

In: International Journal of Pharmaceutics, Vol. 375, No. 1-2, 22.06.2009, p. 148-154.

Research output: Contribution to journalArticle

Ishihara, Tsutomu ; Kubota, Tetsushi ; Choi, Tesu ; Takahashi, Miyuki ; Ayano, Eri ; Kanazawa, Hideko ; Higaki, Megumu. / Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. In: International Journal of Pharmaceutics. 2009 ; Vol. 375, No. 1-2. pp. 148-154.
@article{328b6e5007404c82851f40d3482d1b6f,
title = "Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness",
abstract = "The purpose of this study was to engineer nanoparticles with various sustained profiles of drug release and prolonged circulation by blending poly(d,l-lactic acid)/poly(d,l-lactic/glycolic acid) (PLA/PLGA) homopolymers and poly(ethylene glycol) (PEG)-block-PLA/PLGA copolymers encapsulating betamethasone disodium 21-phosphate (BP). Nanoparticles of different sizes, drug encapsulation/release profiles, and cellular uptake levels were obtained by mixing homopolymers and block copolymers with different compositions/molecular weights at various blend ratios by an oil-in-water solvent diffusion method. The in vitro release of BP increased with nanoparticles of smaller size or of PLGA homopolymers instead of PLA homopolymers. Furthermore, the uptake of nanoparticles by macrophage-like cells decreased with nanoparticles of higher PEG content, and nanoparticles of PEG-PLGA block copolymers were taken up earlier than those of PEG-PLA block copolymers after incubation with serum. In addition, prolonged blood circulation was observed with nanoparticles of smaller size with higher PEG content, and nanoparticles of PEG-PLA block copolymers remained longer in circulation than those of PEG-PLGA block copolymers. Analysis of BP concentration in organs revealed reduced liver distribution of blended nanoparticles compared with PLA nanoparticles. This is the first study to systematically design and characterize biodegradable PLA/PLGA and PEG-PLA/PLGA-blended nanoparticles encapsulating BP with different release profiles and stealthiness.",
keywords = "Betamethasone disodium 21-phosphate, Biodistribution, Drug release, Nanoparticles, PEG, PLA/PLGA polymers",
author = "Tsutomu Ishihara and Tetsushi Kubota and Tesu Choi and Miyuki Takahashi and Eri Ayano and Hideko Kanazawa and Megumu Higaki",
year = "2009",
month = "6",
day = "22",
doi = "10.1016/j.ijpharm.2009.04.001",
language = "English",
volume = "375",
pages = "148--154",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness

AU - Ishihara, Tsutomu

AU - Kubota, Tetsushi

AU - Choi, Tesu

AU - Takahashi, Miyuki

AU - Ayano, Eri

AU - Kanazawa, Hideko

AU - Higaki, Megumu

PY - 2009/6/22

Y1 - 2009/6/22

N2 - The purpose of this study was to engineer nanoparticles with various sustained profiles of drug release and prolonged circulation by blending poly(d,l-lactic acid)/poly(d,l-lactic/glycolic acid) (PLA/PLGA) homopolymers and poly(ethylene glycol) (PEG)-block-PLA/PLGA copolymers encapsulating betamethasone disodium 21-phosphate (BP). Nanoparticles of different sizes, drug encapsulation/release profiles, and cellular uptake levels were obtained by mixing homopolymers and block copolymers with different compositions/molecular weights at various blend ratios by an oil-in-water solvent diffusion method. The in vitro release of BP increased with nanoparticles of smaller size or of PLGA homopolymers instead of PLA homopolymers. Furthermore, the uptake of nanoparticles by macrophage-like cells decreased with nanoparticles of higher PEG content, and nanoparticles of PEG-PLGA block copolymers were taken up earlier than those of PEG-PLA block copolymers after incubation with serum. In addition, prolonged blood circulation was observed with nanoparticles of smaller size with higher PEG content, and nanoparticles of PEG-PLA block copolymers remained longer in circulation than those of PEG-PLGA block copolymers. Analysis of BP concentration in organs revealed reduced liver distribution of blended nanoparticles compared with PLA nanoparticles. This is the first study to systematically design and characterize biodegradable PLA/PLGA and PEG-PLA/PLGA-blended nanoparticles encapsulating BP with different release profiles and stealthiness.

AB - The purpose of this study was to engineer nanoparticles with various sustained profiles of drug release and prolonged circulation by blending poly(d,l-lactic acid)/poly(d,l-lactic/glycolic acid) (PLA/PLGA) homopolymers and poly(ethylene glycol) (PEG)-block-PLA/PLGA copolymers encapsulating betamethasone disodium 21-phosphate (BP). Nanoparticles of different sizes, drug encapsulation/release profiles, and cellular uptake levels were obtained by mixing homopolymers and block copolymers with different compositions/molecular weights at various blend ratios by an oil-in-water solvent diffusion method. The in vitro release of BP increased with nanoparticles of smaller size or of PLGA homopolymers instead of PLA homopolymers. Furthermore, the uptake of nanoparticles by macrophage-like cells decreased with nanoparticles of higher PEG content, and nanoparticles of PEG-PLGA block copolymers were taken up earlier than those of PEG-PLA block copolymers after incubation with serum. In addition, prolonged blood circulation was observed with nanoparticles of smaller size with higher PEG content, and nanoparticles of PEG-PLA block copolymers remained longer in circulation than those of PEG-PLGA block copolymers. Analysis of BP concentration in organs revealed reduced liver distribution of blended nanoparticles compared with PLA nanoparticles. This is the first study to systematically design and characterize biodegradable PLA/PLGA and PEG-PLA/PLGA-blended nanoparticles encapsulating BP with different release profiles and stealthiness.

KW - Betamethasone disodium 21-phosphate

KW - Biodistribution

KW - Drug release

KW - Nanoparticles

KW - PEG

KW - PLA/PLGA polymers

UR - http://www.scopus.com/inward/record.url?scp=67349157140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349157140&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2009.04.001

DO - 10.1016/j.ijpharm.2009.04.001

M3 - Article

C2 - 19481700

AN - SCOPUS:67349157140

VL - 375

SP - 148

EP - 154

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -